Despite troublesome safety problems with past entrants into this market, the veritable epidemic of overweight and obesity continues to make this sector an extremely attractive target for pharmaceutical developers. This new title provides a considered view of the market for medical interventions in the battle against obesity, including U.S. and worldwide market size and growth forecasts, competitive market share and extensive pharmaceutical pipeline information.
The report discusses both prescription and OTC drug markets and surgical interventions. Market size and growth rates are provided through 2010 for:
- Prescription Appetite Suppressants
- Prescription Lipase Inhibitors
- OTC Appetite Suppressants
- OTC Fat Substitutes
- Surgical Intervetion (dollar- and procedure volumes)
Complete epidemilogical data, detailed descriptions of over 50 compounds in development for this sector, and profiles of 14 top suppliers are provided as well.